Author

D. G. Huntsman

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 9 Cell Biology· 1 Pathology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 10 Approach:experimental assay· 8 Assay:bulk RNA-seq· 5 Research Focus:chromatin & epigenetic regulation· 4 Research Focus:differential expression· 4 Research Focus:drug response / drug discovery· 4 Research Focus:cell type annotation· 3 Assay:ChIP-seq· 3

Frequent Co-Authors

Y. Wang· 6 shared A. N. Karnezis· 4 shared B. E. Weissman· 4 shared J. M. Trent· 4 shared P. Pirrotte· 4 shared E. A. Raupach· 3 shared J. D. Lang· 3 shared K. A. Orlando· 3 shared

Activity by Year

2017-2025 · peak 4/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

6 shared papersCancer Biology

Y. Wang

Mutual co-authors in cluster

Author profile →

11 papers

Recent·Most cited

Landscape of super-enhancers in small cell carcinoma of the ovary, hypercalcemic type and efficacy of targeting with natural product triptolide

J. D. Lang, W. Selleck, S. Striker, N. A. Hipschman, R. Kofman, A. N. Karnezis, F. K. Kommoss, F. Kommoss, J. R. Wendt, S. J. Facista, W. P. Hendricks, K. A. Orlando, P. Pirrotte, E. A. Raupach, V. L. Zismann, , J. M. Trent

This paper identifies super-enhancer activity in SCCOHT driven by SMARCA4 loss and shows triptolide effectively inhibits tumor growth by targeting TFIIH at super-enhancers.

iScience · Feb 1, 2025Peer-reviewedCancer Biology

Genome-wide CRISPR screen identifies KEAP1 perturbation as a vulnerability of ARID1A-deficient cells

L.-A. Fournier, F. Kalantari, J. P. Wells, J. S. Lee, G. Trigo-Gonzalez, M. M. Moksa, T. Smith, J. White, A. Shanks, L. Wang, E. Su, Y. Wang, D. G. Huntsman, M. Hirst, P. C. Stirling

The paper identifies KEAP1 as a genetic dependency in ARID1A-deficient clear cell ovarian carcinoma cells through a genome-wide CRISPR screen, showing KEAP1 perturbation leads to growth inhibition.

bioRxiv · Nov 14, 2023Cancer Biology

Modeling High-grade serous ovarian carcinoma using a combination of in vivo electroporation and CRISPR/Cas9 mediated genome editing

K. Teng, M. J. Ford, K. Harwalkar, Y. Li, D. Farnell, N. Yamanaka, T. N. Tuyet Nhung, D. G. Huntsman, J. Arseneau, Y. Yamanaka

This paper develops a method to generate HGSC mouse models using in vivo electroporation and CRISPR/Cas9, showing that specific gene mutations lead to different tumor characteristics.

bioRxiv · Mar 29, 2021Cancer Biology

ARID1A regulates R-loop associated DNA replication stress

P. Stirling, S. Tsai, E. Y.-C. Chang, L.-A. Fournier, J. P. Wells, S. W. Minaker, Y. D. Zhu, A. Y.-H. Wang, Y. Wang, D. G. Huntsman

This study shows that ARID1A loss causes DNA replication stress linked to R-loops and transcription-replication conflicts in human cells.

bioRxiv · Nov 16, 2020Cell Biology

Primary platinum resistance and immune exclusion in ovarian carcinomas with high expression of the homologous recombination mediator RAD51

M. M. Hoppe, T. Z. Tan, S. Lie, S. Lim, J. P. Yeong, J. D. Wardyn, P. Jaynes, D. G. Lim, B. N. Pang, A. Karnezis, D. Chiu, S. Leung, D. G. Huntsman, A. S. Sedukhina, K. Sato, , A. Jeyasekharan

This study shows that high RAD51 expression in ovarian cancer is linked to poor survival and platinum resistance, particularly in HRD-negative tumors, and correlates with immune exclusion.

bioRxiv · Jun 9, 2020Cancer Biology

The pathognomonic FOXL2 C134W mutation alters DNA binding specificity

A. Carles, G. Trigo-Gonzalez, R. Cao, S.- W. G. Cheng, M. Moksa, M. Bilenky, G. B. Morin, D. G. Huntsman, M. Hirst

This study investigates the molecular effects of the FOXL2 C134W mutation in AGCT by analyzing DNA binding and transcriptome changes in engineered cell lines.

bioRxiv · Mar 20, 2020Cancer Biology

Arginine depletion through ADI-PEG20 to treat argininosuccinate synthase deficient ovarian cancer, including small cell carcinoma of the ovary, hypercalcemic type

J. X. Ji, D. R. Cochrane, B. Tessier-Cloutier, S. Chen, G. Ho, K. V. Pathak, I. Alcazar, D. Farnell, S. Leung, A. Cheng, C. Chow, S. Colborne, G. Luca Negri, F. Kommoss, A. N. Karnezis, , D. G. Huntsman

This paper identifies ASS1 deficiency in rare ovarian cancers and shows that ADI-PEG20 inhibits tumor growth in ASS1-deficient models.

bioRxiv · Nov 17, 2019 · PreprintCancer Biology

Novel functional insights revealed by distinct protein-protein interactions of the residual SWI/SNF complex in SMARCA4-deficient small cell carcinoma of the ovary, hypercalcemic type

E. A. Raupach, K. Garcia-Mansfield, R. Sharma, A. M. Hegde, V. David-Dirgo, Y. Wang, C. Young Shin, L. V. Tao, S. J. Facista, R. Moore, J. D. Lang, V. L. Zismann, K. A. Orlando, M. Spillman, A. N. Karnezis, , P. Pirrotte

This study identifies distinct protein-protein interactions of the residual SWI/SNF complex in SMARCA4-deficient SCCOHT cell lines, revealing altered functional consequences and potential synthetic lethal targets.

bioRxiv · Oct 6, 2019 · PreprintCancer Biology

Oncogenic Mutations in Histologically Normal Endometrium: The New Normal?

V. Lac, T. M. Nazeran, B. Tessier-Cloutier, R. Aguirre-Hernandez, A. Albert, A. Lum, J. Khattra, T. Praetorius, M. Mason, D. Chiu, M. Köbel, P. J. Yong, B. C. Gilks, M. S. Anglesio, D. G. Huntsman

This study finds that over 50% of histologically normal endometrium samples contain somatic driver mutations, including KRAS, PIK3CA, FGFR2, and PTEN loss, with prevalence increasing with age.

bioRxiv · Feb 26, 2019Pathology

Non-coding Somatic Mutations Converge on the PAX8 Pathway in Epithelial Ovarian Cancer

R. I. Corona, J.-H. Seo, X. Lin, D. J. Hazelett, J. Reddy, F. Abassi, Y. G. Lin, P. Y. Mhawech-Fauceglia, J. Lester, S. P. Shah, D. G. Huntsman, A. Gusev, B. Y. Karlan, B. P. Berman, M. L. Freedman, , K. Lawrenson

The paper identifies histotype-specific regulatory elements in ovarian cancer by integrating chromatin landscapes and somatic mutations, highlighting the PAX8 pathway's role in tumor development.

bioRxiv · Feb 1, 2019Cancer Biology

Ponatinib shows potent antitumor activity in small cell carcinoma of the ovary hypercalcemic type (SCCOHT) through multi-kinase inhibition

J. D. Lang, W. P. D. Hendricks, H. Yin, J. Kiefer, P. Ramos, R. Sharma, P. Pirrotte, E. A. Raupach, C. Sereduk, N. Tang, W. S. Liang, M. Washington, S. J. Facista, V. L. Zismann, E. M. Cousins, , J. M. Trent

This paper identifies ponatinib as a potent treatment for SCCOHT by inhibiting multiple kinases in preclinical models.

bioRxiv · Jul 6, 2017Cancer Biology